Aplastic anaemia
Also known as: Aplastic anemia, Acquired aplastic anaemia, Hypoplastic anaemia, Aplastic bone marrow failure
Aplastic anaemia is characterised by bone marrow failure resulting in pancytopenia. The condition carries significant risks of severe anaemia, life-threatening infection, and haemorrhage. Primary clinical management is provided by haematologists and typically involves blood transfusions, immunosuppressive therapy, or haematopoietic stem cell transplantation [1, 2]. Cited evidence includes a review of genetic susceptibility, a retrospective analysis of transplant outcomes, and a case report concerning zidovudine [1, 2, 3]. There is no clinical evidence that acupuncture or Chinese herbal medicine enhances marrow function, haematological parameters, or survival rates. TCM patterns provide traditional frameworks for symptomatic management and are not biomedical equivalents or substitutes for medical intervention. Adjunctive care requires prior haematological approval following review of current blood counts and potential pharmaceutical interactions, particularly during immunosuppression or transplantation. Safety precautions are conservative clinical safeguards rather than protocols established by these abstracts.
Plain-English one-pager you can print or hand to a patient. Free, no sign-in needed.
Lifestyle & Diet
- •Prioritise all haematological consultations and pathology monitoring; maintain a comprehensive, current record of all pharmaceutical and supplementary agents.
- •Adopt a balance of rest and medically approved gentle activity, ensuring the avoidance of movements associated with a high risk of falls or trauma.
- •Adhere strictly to all infection-prevention and food-safety advice provided by the treating medical team; report any febrile episode immediately.
- •Maintain adequate nutritional intake as tolerated; refrain from iron or folate supplementation unless specifically indicated, particularly in the context of regular transfusions.
Cautions & Contraindications
- •Defer skin-penetrating acupuncture with active bleeding, clinically significant thrombocytopenia, severe neutropenia, fever or unstable illness until the haematologist explicitly clears it. The supplied marrow-failure and transplant records contextualise risk but establish no safe needling thresholds.[,]
- •Do not initiate herbal formulas during conditioning, transplantation or complex immunosuppression without transplant-team and pharmacist approval. The transplantation study does not evaluate herbal interactions or safety.[]
- •Do not independently withdraw prescribed medicines or copy the iron and folate regimen from the zidovudine case report; medication changes and supplementation require individual medical assessment.[]
When to reassess or seek care again
If adjunctive care is approved, review tolerability within 48–72 hours and symptom outcomes after 1–2 weeks, recording fatigue on a 0–10 scale, sleep duration, appetite and daily activity tolerance. Confirm current blood results and medical clearance before each invasive session; laboratory monitoring remains haematology-led. Stop and refer immediately for red flags or suspected adverse effects. Refer back for worsening fatigue or declining function; discontinue an ineffective adjunct rather than escalating treatment. Never attribute blood-count changes to TCM without appropriate evidence.
Explore more diseases
Sources & Further Reading
Clinical guidance, red flags and safety notes on this page draw on the following current sources alongside the classical references above.
- Scandinavian journal of immunology · 2026
- Annals of medicine · 2026
- BMC infectious diseases · 2024
Educational reference for licensed practitioners. Not a substitute for individual clinical assessment. Refer to conventional care for any red-flag or undiagnosed presentation.
